Table 2.
Efficacy of rituximab therapy in RA and AA amyloidosis: Briefly; A review of the literature.
| Author (Reference)/Year of Publication | Age/Sex | Disease Duration (Years) | Treatment before RTX | Concomitant Therapy | Follow-Up (Months) | Creatinine (Initial-Last) (mg/dL) | Proteinuria (Initial-Last) (g/day) | CRP (Initial-Last) (mg/L) | DAS 28 (Initial-Last) | Efficacy for Underlying Diseases |
|---|---|---|---|---|---|---|---|---|---|---|
| Narváez et al. 2010 [14] | F/46 | 14 | AZA, CQ, CsA, LEF, MTX, IFX, ETA, ADM | - | 41 (7 cycle) | 1.05–1.09 | 0.44–0.15 | 110–18 | 7.68–5.24 | + |
| F/75 | 28 | GS, CQ, DP, LEF, MTX, SSZ, IFX, | - | 22 (2 cycle) | 2.52–2.58 | 0.94–1.22 | 12.6–9.5 | 6.53–3.35 | + | |
| F/56 | 40 | GS, DP, CQ, LEF, MTX, ADM | MTX 12.5 mg/w | 15 (3 cycle) | 2.16–2.10 | 0.29–0.19 | 15.8–6.5 | 5.72–3.98 | + | |
| F/67 | 16 | GS, CQ, SSZ, MTX, IFX, | MTX 10 mg/w | 12 (3 cycle) | 1.99–1.58 | 1.75–0.65 | 17–3.6 | 7.81–4.35 | + | |
| Burkart et al. 2012 [13] | F/61 | 34 | (DMARD therapy N/A) ETA, ADM | N/A | 18 | N/A | N/A | N/A | N/A | + |
| Pamuk et al. 2013 [11] | M/50 | 11 | CS, SSZ, HCQ | N/A | 10 | 2.7–1.8 | 1.4–0.3 | N/A | N/A | + |
| Our study Kilic et al. | F/56 (P1) | 22 | MTX, SSZ, HCQ, LEF, CS, ETA, ADM | LEF 20 mg/d CS 5 mg/d | 96 | 1.6–1.56 | 4.8–0.4 | 65–12 | 7.7–4.49 | + |
| F/59 (P2) | 19 | MTX, SSZ, LEF, CS | CS 5 mg/d | 6 | 1.8–1.9 | 4.5–0.3 | 5.4–12 | 5.1–6.2 | - |
ADM: adalimumab; AZA: azathioprine; CQ: chloroquine; CRP: C-reactive protein; CS: corticosteroid; CsA: ciclosporin A; DAS28: disease activity score in 28 joints; DP: D-penicillamine; ESR: erythrocyte sedimentation rate; ETA: etanercept; GS: gold salts; HCQ: hydroxychloroquine; IFX: infliximab; MTX: methotrexate; LEF; leflunomide; SSZ: sulfasalazine. DMARD: disease modifying anti-rheumatic drugs; N/A: Not available.